239 related articles for article (PubMed ID: 21917975)
1. Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation.
Alam SM; Liao HX; Dennison SM; Jaeger F; Parks R; Anasti K; Foulger A; Donathan M; Lucas J; Verkoczy L; Nicely N; Tomaras GD; Kelsoe G; Chen B; Kepler TB; Haynes BF
J Virol; 2011 Nov; 85(22):11725-31. PubMed ID: 21917975
[TBL] [Abstract][Full Text] [Related]
2. Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function.
Guenaga J; Wyatt RT
PLoS Pathog; 2012; 8(7):e1002806. PubMed ID: 22829767
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41.
Chen J; Frey G; Peng H; Rits-Volloch S; Garrity J; Seaman MS; Chen B
J Virol; 2014 Jan; 88(2):1249-58. PubMed ID: 24227838
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6.
Ofek G; Zirkle B; Yang Y; Zhu Z; McKee K; Zhang B; Chuang GY; Georgiev IS; O'Dell S; Doria-Rose N; Mascola JR; Dimitrov DS; Kwong PD
J Virol; 2014 Mar; 88(5):2426-41. PubMed ID: 24335316
[TBL] [Abstract][Full Text] [Related]
5. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding.
Julien JP; Huarte N; Maeso R; Taneva SG; Cunningham A; Nieva JL; Pai EF
J Virol; 2010 May; 84(9):4136-47. PubMed ID: 20147404
[TBL] [Abstract][Full Text] [Related]
6. Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies.
Ma BJ; Alam SM; Go EP; Lu X; Desaire H; Tomaras GD; Bowman C; Sutherland LL; Scearce RM; Santra S; Letvin NL; Kepler TB; Liao HX; Haynes BF
PLoS Pathog; 2011 Sep; 7(9):e1002200. PubMed ID: 21909262
[TBL] [Abstract][Full Text] [Related]
7. Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody.
Tudor D; Yu H; Maupetit J; Drillet AS; Bouceba T; Schwartz-Cornil I; Lopalco L; Tuffery P; Bomsel M
Proc Natl Acad Sci U S A; 2012 Jul; 109(31):12680-5. PubMed ID: 22723360
[TBL] [Abstract][Full Text] [Related]
8. Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10.
Chen Y; Zhang J; Hwang KK; Bouton-Verville H; Xia SM; Newman A; Ouyang YB; Haynes BF; Verkoczy L
J Immunol; 2013 Aug; 191(3):1260-75. PubMed ID: 23825311
[TBL] [Abstract][Full Text] [Related]
9. Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8.
Soto C; Ofek G; Joyce MG; Zhang B; McKee K; Longo NS; Yang Y; Huang J; Parks R; Eudailey J; Lloyd KE; Alam SM; Haynes BF; ; Mullikin JC; Connors M; Mascola JR; Shapiro L; Kwong PD
PLoS One; 2016; 11(6):e0157409. PubMed ID: 27299673
[TBL] [Abstract][Full Text] [Related]
10. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.
Ofek G; Tang M; Sambor A; Katinger H; Mascola JR; Wyatt R; Kwong PD
J Virol; 2004 Oct; 78(19):10724-37. PubMed ID: 15367639
[TBL] [Abstract][Full Text] [Related]
11. Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses.
Verkoczy L; Chen Y; Zhang J; Bouton-Verville H; Newman A; Lockwood B; Scearce RM; Montefiori DC; Dennison SM; Xia SM; Hwang KK; Liao HX; Alam SM; Haynes BF
J Immunol; 2013 Sep; 191(5):2538-50. PubMed ID: 23918977
[TBL] [Abstract][Full Text] [Related]
12. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region.
Ofek G; McKee K; Yang Y; Yang ZY; Skinner J; Guenaga FJ; Wyatt R; Zwick MB; Nabel GJ; Mascola JR; Kwong PD
J Virol; 2010 Mar; 84(6):2955-62. PubMed ID: 20042512
[TBL] [Abstract][Full Text] [Related]
13. N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies.
Li D; Liu J; Zhang L; Xu T; Chen J; Wang L; Zhao Q
Virol Sin; 2015 Dec; 30(6):449-56. PubMed ID: 26715302
[TBL] [Abstract][Full Text] [Related]
14. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.
Alam SM; McAdams M; Boren D; Rak M; Scearce RM; Gao F; Camacho ZT; Gewirth D; Kelsoe G; Chen P; Haynes BF
J Immunol; 2007 Apr; 178(7):4424-35. PubMed ID: 17372000
[TBL] [Abstract][Full Text] [Related]
15. Construction of recombinant targeting immunogens incorporating an HIV-1 neutralizing epitope into sites of differing conformational constraint.
Ho J; MacDonald KS; Barber BH
Vaccine; 2002 Jan; 20(7-8):1169-80. PubMed ID: 11803079
[TBL] [Abstract][Full Text] [Related]
16. A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1.
Lai RP; Hock M; Radzimanowski J; Tonks P; Hulsik DL; Effantin G; Seilly DJ; Dreja H; Kliche A; Wagner R; Barnett SW; Tumba N; Morris L; LaBranche CC; Montefiori DC; Seaman MS; Heeney JL; Weissenhorn W
J Biol Chem; 2014 Oct; 289(43):29912-26. PubMed ID: 25160627
[TBL] [Abstract][Full Text] [Related]
17. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies.
Yang G; Holl TM; Liu Y; Li Y; Lu X; Nicely NI; Kepler TB; Alam SM; Liao HX; Cain DW; Spicer L; VandeBerg JL; Haynes BF; Kelsoe G
J Exp Med; 2013 Feb; 210(2):241-56. PubMed ID: 23359068
[TBL] [Abstract][Full Text] [Related]
18. Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization.
Maeso R; Huarte N; Julien JP; Kunert R; Pai EF; Nieva JL
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):863-76. PubMed ID: 21142698
[TBL] [Abstract][Full Text] [Related]
19. Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies.
Zhu Z; Qin HR; Chen W; Zhao Q; Shen X; Schutte R; Wang Y; Ofek G; Streaker E; Prabakaran P; Fouda GG; Liao HX; Owens J; Louder M; Yang Y; Klaric KA; Moody MA; Mascola JR; Scott JK; Kwong PD; Montefiori D; Haynes BF; Tomaras GD; Dimitrov DS
J Virol; 2011 Nov; 85(21):11401-8. PubMed ID: 21880764
[TBL] [Abstract][Full Text] [Related]
20. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5.
Zwick MB; Komori HK; Stanfield RL; Church S; Wang M; Parren PW; Kunert R; Katinger H; Wilson IA; Burton DR
J Virol; 2004 Mar; 78(6):3155-61. PubMed ID: 14990736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
